 TEL AVIV, Israel, April 13, 2021 GLOBE NEWSWIRE -- Purple Biotech Ltd. Purple Biotech , or the Company NASDAQTASE: PPBT, a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced that additional preclinical data supporting the mechanism of action of NT219, a dual inhibitor, novel small molecule that simultaneously targets IRS12 and STAT3, were presented in a poster entitled Adaptation of colorectal cancer cells to the brain microenvironment: The role of IRS2, at the American Association of Cancer Research AACR 2021 Annual Meeting. These data update and expand on the results previously reported by the Company from its collaboration with Professor Ido Wolf, Head of the Oncology Division at Tel Aviv Sourasky Medical Center. 